Publication | Open Access

Circulating endothelial cells and endothelial progenitors as predictive markers of clinical response to bevacizumab-based first-line treatment in advanced colorectal cancer patients

Bevacizumab-based First-line TreatmentEndothelial CellsEndothelial ProgenitorsMedicineImmunologyPathologyColorectal CancerImmune Checkpoint InhibitorVascular BiologyCancer TreatmentOncologyTumor MicroenvironmentCancer Research